TABLE 1.

In vitro antiviral activity of rupintrivir against HRV clinical isolates and HEV^a

Virus	Antiviral activity
	EC50 (nM)	EC90 (nM)
HRV clinical isolateb
100	22 ± 20	32 ± 8
103	58, 24	316, 746
108	43, 19	182, 42
113	46, 26	464
119	29 ± 11	145 ± 130
123	23	ND
126	23	794
129	19	39
142	19	38
O	54 ± 51	275 ± 258
G	14, 20	66, 1078
I	104, 16	604, 29
W	10, 3	44, 7
J	18 ± 6	69 ± 90
R	14 ± 8	204 ± 291
Q	17	33
B	12	40
C	12	28
T	42 ± 28	123 ± 24
E	23	562
15	26 ± 7	262
28	8	18
32	7	19
Enterovirus
CVB 2	22, 137	88, 254
CVB 5	7, 47	147, 83
EV 6	51, 34	94, 59
EV 9	11, 18	65, 34

^aAntiviral activity was determined by measuring XTT dye reduction following 2 to 7 days of infection by using the standard or modified CPE inhibition assays as described in Materials and Methods. Results represent the mean ± standard deviation (three to five experiments) or individual values (one or two experiments). ND, not determined.

^bClinical isolates were derived from nasal lavage samples collected from subjects infected with HRV serotype 39 (designated 100, 103, 108, 113, 119, 123, 126, 129, 142, O, G, I, W), Hanks (designated J, R, Q, and B), 16 (designated C, T, and E), or 23 (designated 15, 28, and 32).